
Opinion|Videos|January 24, 2025
GOLD 2025 Report: Prebronchodilator Spirometry and Diagnosis of COPD
Panelists discuss the initial thought that postbronchodilator spirometry would help differentiate chronic obstructive pulmonary disease (COPD) from asthma. However, postbronchodilator spirometry adds time and effort, as well as exposing a patient to short-term medication that may have adverse effects. Guidelines favor a fixed ratio of forced expiratory volume in the first second to forced vital capacity (FEV1/FVC; < 0.7) because of the ratio’s simplicity and is independent of other reference values.
Advertisement
Episodes in this series

Video content above is prompted by the following:
- Why is postbronchodilator spirometry no longer recommended in the Global Initiative for Chronic Obstructive Lung Disease (GOLD) 2025 Report as the first step in confirming a diagnosis of COPD?
- How do the results of prebronchodilator spirometry further guide a COPD diagnosis?
- Why do the guidelines favor a fixed FEV1/FVC ratio (<0.7) over a lower limit of normal as a diagnostic criterion for COPD?
Advertisement
Related to this article

Gerard Criner, MD, reviews GOLD 2026 sessions on mucus plugs and inhaler technique, plus multimorbidity, exacerbation risk, and the 2027 GOLD Report.

Children receiving 50 nmol PVX108 increased their tolerated peanut dose 2.4-fold, with no treatment-related anaphylaxis in the phase 2 trial.

Ackerman and Bunick review 52-week AMETHYST data for litifilimab in refractory cutaneous lupus and make the case for dermatology-led CLE care.

Lawrence Eichenfield, MD, discusses phase 2 nemolizumab data in children aged 2 - 11 with atopic dermatitis, from caregiver-rated itch to sleep gains.

In this Q&A, Jennifer K. Priessnitz, MD, explains why FAERS reporting proportions should not drive biologic selection and what data are needed next.

At ACAAI 2026, Jennifer Priessnitz, MD presented data which found omalizumab had the highest anaphylaxis reporting proportion among 7 respiratory biologics.

Pooled, blinded week 12 data from the phase 2 RENEW trial showed FVC improvement in 8 of 24 patients with IPF and no treatment-related serious AEs.
Advertisement
Advertisement
Trending on HCPLive
1
Single Annual Injection Produces Significant and Sustained Lp(a) Reductions
2
Ruvonoflast Reduces hsCRP, Inflammation, CVD Risk With Downstream Effects
3
Lessons From ZEUS on Targeting Inflammation, With Peter Libby, MD
4
SUMMIT Substudy Reveals Tirzepatide’s Impact on LV, Atrial Metrics of HFpEF
5

